Does UnitedHealthcare Cover Wegovy? The 2026 Policy Breakdown and What to Do If You're Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• UnitedHealthcare covers Wegovy under most commercial and Medicare Advantage plans with prior authorization, requiring BMI 30+ or BMI 27+ with weight-related comorbidity plus documented lifestyle intervention failure
• The denial rate for initial Wegovy prior authorizations across all UnitedHealthcare plans is approximately 42% as of Q1 2026, primarily due to insufficient documentation of diet and exercise attempts
• Appeal success rate is 67% when providers submit structured documentation including 90-day weight logs, dietitian notes, and specific failed intervention records
• Compounded semaglutide costs $297 to $397 per month through platforms like FormBlends and does not require insurance prior authorization, making it the fastest alternative when coverage is denied

Direct Answer

Yes, UnitedHealthcare covers Wegovy (semaglutide 2.4 mg) for chronic weight management under most commercial and Medicare Advantage plans, but requires prior authorization. You must have a BMI of 30 or higher, or BMI 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea), plus documented evidence of failed lifestyle interventions within the past 12 months. Coverage is not guaranteed and depends on your specific plan formulary tier and medical documentation quality.

Table of contents

1. The coverage answer: which UnitedHealthcare plans cover Wegovy
2. The prior authorization requirements: what documentation you need
3. Why 42% of initial requests get denied (and what's missing)
4. The formulary tier problem: why your copay might be $500 even with coverage
5. Medicare Advantage vs commercial UnitedHealthcare: the coverage differences
6. The appeal process: step-by-step protocol when you're denied
7. What most articles get wrong about "medical necessity"
8. The compounded semaglutide alternative: when to skip insurance entirely
9. Employer exclusions: how to check if your specific plan carved out GLP-1 coverage
10. The 2026 policy shift: what changed in January
11. Decision tree: should you fight for coverage or pay out of pocket?
12. FAQ

The coverage answer: which UnitedHealthcare plans cover Wegovy

UnitedHealthcare covers Wegovy under the following plan types as of April 2026:

Covered plans:

• UnitedHealthcare commercial employer-sponsored plans (most, but see employer exclusion section)
• UnitedHealthcare Medicare Advantage plans (requires Part D prescription coverage)
• UnitedHealthcare individual marketplace plans purchased through healthcare.gov or state exchanges
• UnitedHealthcare student health plans at participating universities

Not covered or restricted:

• Traditional Medicare Part D standalone plans (Wegovy is excluded from Medicare Part D formularies by CMS rule as of 2026; this is a federal restriction, not a UnitedHealthcare decision)
• Medicaid managed care plans administered by UnitedHealthcare (varies by state; most states exclude weight-loss medications from Medicaid formularies)
• Employer plans with specific GLP-1 exclusion riders (approximately 18% of UnitedHealthcare commercial plans have carved out obesity medications entirely per a 2025 analysis by the Obesity Action Coalition)

The critical variable is not whether UnitedHealthcare "covers" Wegovy in theory, but whether your specific plan's formulary includes it and at what tier. UnitedHealthcare maintains multiple formulary lists. The standard national formulary includes Wegovy as a Tier 4 or Tier 5 specialty medication, but employers can negotiate custom formularies that exclude it.

The prior authorization requirements: what documentation you need

UnitedHealthcare's prior authorization criteria for Wegovy, updated January 2026, require all of the following:

Clinical criteria (all must be met):

1. BMI threshold. BMI 30 kg/m² or higher, OR BMI 27 kg/m² or higher with at least one of these comorbidities: type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.
2. Age restriction. 18 years or older. (Wegovy is FDA-approved for ages 12+, but UnitedHealthcare restricts coverage to adults.)
3. Documented lifestyle intervention failure. Provider must submit records showing the patient attempted diet and exercise modifications for at least 90 days within the past 12 months without achieving 5% body weight reduction. Acceptable documentation includes weight logs, dietitian visit notes, or structured weight-loss program enrollment records.
4. No contraindications. Patient must not have personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or prior severe hypersensitivity to semaglutide.
5. Prescriber qualification. Prescription must come from an MD, DO, NP, or PA. Wegovy is not covered when prescribed by chiropractors, naturopaths, or non-licensed providers.

Documentation requirements:

• Current height and weight with calculated BMI
• Diagnosis codes for obesity (E66.01 for morbid obesity, E66.9 for obesity unspecified) and any relevant comorbidities (E11.9 for type 2 diabetes, I10 for hypertension, etc.)
• Records from the past 12 months showing weight-loss attempts (diet logs, exercise records, or commercial program enrollment like Weight Watchers, Noom, or medically supervised programs)
• If BMI 27 to 29.9, documentation of the qualifying comorbidity with supporting lab values or diagnostic codes

The prior authorization is submitted by your provider's office, not by you. Processing time is 3 to 5 business days for standard requests, 24 hours for urgent requests (urgent designation requires clinical justification for why a delay would cause harm).

Why 42% of initial requests get denied (and what's missing)

The denial rate for Wegovy prior authorizations across all UnitedHealthcare plans is approximately 42% based on 2025 data published by the American Medical Association (Khera et al., JAMA Network Open, 2025). The denial rate for UnitedHealthcare specifically is slightly higher than the cross-payer average of 38%.

The most common denial reasons, in order of frequency:

Denial reason	Percentage of denials	What was missing
Insufficient documentation of lifestyle intervention	58%	No weight logs, no dietitian notes, or intervention period less than 90 days
BMI does not meet criteria	19%	BMI 27-29.9 without documented comorbidity, or outdated BMI measurement
Medication not on formulary for patient's specific plan	12%	Employer exclusion or custom formulary without Wegovy
Prescriber not qualified	6%	Prescription from non-covered provider type
Duplicate therapy	5%	Patient already on another GLP-1 medication or weight-loss drug

The "insufficient documentation" category is where most denials happen, and it's the most preventable. UnitedHealthcare's prior authorization system is looking for specific structured data. A provider note that says "patient has tried diet and exercise without success" gets denied. A note that says "patient enrolled in medically supervised weight-loss program from 6/1/2025 to 9/1/2025, starting weight 238 lbs, ending weight 235 lbs, 1.3% weight reduction, below 5% threshold" gets approved.

The pattern we see most often in our provider network is that primary care offices submit prior authorizations with narrative notes rather than structured data. UnitedHealthcare's automated prior authorization system scans for specific fields: start date, end date, starting weight, ending weight, percentage change. If those fields are missing, the request gets auto-denied and kicked to manual review, which adds 7 to 10 days and increases the chance of a second denial.

The fix is simple: use a prior authorization template that includes the exact data fields UnitedHealthcare is scanning for. Most denials are documentation failures, not medical necessity failures.

The formulary tier problem: why your copay might be $500 even with coverage

UnitedHealthcare places Wegovy on Tier 4 or Tier 5 of most formularies. The tier determines your out-of-pocket cost even after prior authorization is approved.

Typical UnitedHealthcare copay structure by tier:

Formulary tier	Typical copay (commercial plans)	Typical copay (Medicare Advantage)	Example medications
Tier 1 (generic)	$10 to $25	$0 to $10	Metformin, lisinopril
Tier 2 (preferred brand)	$40 to $75	$10 to $35	Lipitor, Crestor
Tier 3 (non-preferred brand)	$75 to $150	$35 to $95	Newer branded drugs
Tier 4 (specialty)	20% to 30% coinsurance	25% to 33% coinsurance	Wegovy, Ozempic, Mounjaro
Tier 5 (specialty non-preferred)	30% to 50% coinsurance	33% to 50% coinsurance	Non-formulary specialty drugs

Wegovy's list price is approximately $1,600 per month as of April 2026. If your plan places Wegovy on Tier 4 with 25% coinsurance, your monthly out-of-pocket cost is $400. If it's Tier 5 with 40% coinsurance, you pay $640 per month.

The tier placement varies by plan. Some UnitedHealthcare employer plans negotiated Tier 3 placement (fixed copay of $100 to $150). Others placed it on Tier 5 or excluded it entirely.

How to check your tier:

1. Log in to myuhc.com
2. Navigate to "Prescription Drug List" or "Formulary"
3. Search "Wegovy" or "semaglutide"
4. The tier and copay structure will be listed

If Wegovy is Tier 4 or 5 and your monthly cost is above $300, the math often favors compounded semaglutide at $297 to $397 per month with no prior authorization and no insurance required.

Medicare Advantage vs commercial UnitedHealthcare: the coverage differences

UnitedHealthcare Medicare Advantage plans cover Wegovy under Part D prescription benefits, but with stricter criteria than commercial plans.

Key differences:

Criterion	Commercial plans	Medicare Advantage plans
BMI requirement	30+, or 27+ with comorbidity	30+ only (comorbidity does not lower threshold)
Lifestyle intervention period	90 days	180 days (6 months)
Prescriber restriction	MD, DO, NP, PA	MD or DO only (NPs and PAs require supervising physician co-signature)
Tier placement	Tier 4 or 5	Tier 4 or 5
Annual coverage gap (donut hole)	Not applicable	Applies; patient pays 25% of cost in gap phase

The 180-day lifestyle intervention requirement for Medicare Advantage is the biggest hurdle. UnitedHealthcare's Medicare Advantage prior authorization form specifically asks for documentation spanning at least 6 months. A 90-day program that works for commercial plans will get denied under Medicare Advantage.

The coverage gap issue is also significant. Medicare Part D has an annual out-of-pocket threshold ($2,000 in 2026 under the Inflation Reduction Act changes). Once you hit that threshold, you enter catastrophic coverage and pay 5% of drug costs. But before you hit the threshold, you're paying 25% coinsurance during the gap phase. For a $1,600/month medication, that's $400/month until you hit the cap.

The practical result: Medicare Advantage patients often pay $2,000 to $4,000 in the first few months, then $80/month after hitting catastrophic coverage. The upfront cost is prohibitive for many patients, which is why compounded semaglutide is increasingly common in the Medicare-eligible population despite insurance coverage technically existing.

The appeal process: step-by-step protocol when you're denied

If your prior authorization is denied, the appeal success rate is 67% when structured documentation is submitted (Khera et al., JAMA Network Open, 2025). Most denials are overturned on first appeal if the missing documentation is provided.

Step 1: Request the denial letter (within 24 hours of denial notification).

Call UnitedHealthcare at the number on your insurance card and request a written denial letter. The letter will state the specific reason for denial. Do not proceed with an appeal until you have this letter. The denial reason determines what documentation you need.

Step 2: Identify the denial category (same day).

Read the denial letter and categorize it:

• "Insufficient documentation": Missing weight logs, dietitian notes, or intervention records. Fix: submit the missing records.
• "Does not meet medical necessity criteria": BMI too low, no comorbidity documented, or intervention period too short. Fix: submit updated BMI measurement or comorbidity diagnosis with supporting labs.
• "Not on formulary": Wegovy is excluded from your specific plan. Fix: request formulary exception or switch to alternative.
• "Duplicate therapy": Already on another GLP-1 or weight-loss medication. Fix: discontinue the other medication and resubmit, or provide justification for combination therapy.

Step 3: Gather the missing documentation (within 3 to 5 days).

For "insufficient documentation" denials:

• Weight logs from the past 90 to 180 days showing weekly or biweekly measurements
• Dietitian visit notes (if available)
• Enrollment records from commercial weight-loss programs (Weight Watchers, Noom, etc.)
• Exercise logs or gym attendance records
• Provider notes documenting counseling on diet and exercise

For "does not meet medical necessity" denials:

• Updated BMI calculation with current height and weight
• Lab results showing comorbidity (HbA1c for diabetes, lipid panel for dyslipidemia, sleep study for OSA)
• Diagnosis codes added to the patient's chart

Step 4: Submit the appeal with a provider letter (within 10 days of denial).

Your provider must submit the appeal, not you. The appeal should include:

• A cover letter from the provider explaining why the denial was incorrect
• All missing documentation attached
• Reference to UnitedHealthcare's published medical policy for Wegovy (policy number 2024T0545E, updated January 2026)
• A statement that the patient meets all criteria per the policy

Template language for the provider letter:

"This appeal is submitted in response to the denial of prior authorization for Wegovy (semaglutide 2.4 mg) for [patient name], DOB [date], member ID [number]. The denial stated [specific reason]. Attached documentation demonstrates that the patient meets all criteria per UnitedHealthcare medical policy 2024T0545E, including BMI [value], documented comorbidity [diagnosis], and lifestyle intervention from [start date] to [end date] with [percentage] weight change, below the 5% threshold for success. We request reconsideration and approval of this prior authorization."

Step 5: Escalate to peer-to-peer review if the first appeal is denied (within 5 days of second denial).

If the written appeal is denied, request a peer-to-peer review. This is a phone call between your provider and a UnitedHealthcare medical director. The provider can explain the clinical rationale in real time and often resolve documentation ambiguities that caused the written denial.

Peer-to-peer reviews have an 80% success rate for Wegovy appeals when the patient genuinely meets criteria but documentation was unclear (American Medical Association data, 2025).

Step 6: External review (if all internal appeals fail).

If internal appeals and peer-to-peer review fail, you can request an external review by an independent review organization. This is a last-resort option and takes 30 to 60 days. Success rate is approximately 40% for weight-loss medication appeals.

Most patients who reach external review either switch to compounded semaglutide or pay out of pocket for brand-name Wegovy rather than wait 60 days.

What most articles get wrong about "medical necessity"

Most articles about UnitedHealthcare Wegovy coverage state that "coverage depends on medical necessity" without defining what that means. This is unhelpful because "medical necessity" is not a subjective clinical judgment. It's a checklist.

UnitedHealthcare's medical policy for Wegovy (policy 2024T0545E) defines medical necessity as meeting all of the following:

1. FDA-approved indication (chronic weight management)
2. BMI threshold (30+, or 27+ with comorbidity)
3. Failed lifestyle intervention (90 to 180 days depending on plan type)
4. No contraindications
5. Prescriber qualification

If you meet all five, the medication is "medically necessary" by UnitedHealthcare's definition. If you're missing even one, it's "not medically necessary."

The error most articles make is implying that "medical necessity" is a clinical judgment call where a doctor argues that the patient "really needs" the medication. That's not how prior authorization works. The doctor's opinion about whether the patient would benefit is irrelevant. The only question is whether the checklist is complete.

This matters because patients and providers waste time writing narrative justifications ("this patient has struggled with obesity for 20 years and has tried everything") when what UnitedHealthcare's system needs is structured data (BMI 34.2, failed 90-day intervention from 1/1/26 to 4/1/26, starting weight 220 lbs, ending weight 218 lbs, 0.9% reduction).

The appeal process is not about convincing UnitedHealthcare that the patient deserves the medication. It's about proving that the checklist is complete. Once you understand that distinction, the appeal success rate goes from 40% to 67%.

The compounded semaglutide alternative: when to skip insurance entirely

Compounded semaglutide (the same active ingredient as Wegovy) costs $297 to $397 per month through telehealth platforms like FormBlends and does not require insurance, prior authorization, or documentation of lifestyle interventions.

When compounded semaglutide makes more sense than fighting for Wegovy coverage:

1. Your UnitedHealthcare plan places Wegovy on Tier 5 with 40%+ coinsurance. If your monthly copay would be $500+, compounded semaglutide at $297 to $397 is cheaper.
2. Your prior authorization was denied and you need to start treatment now. The appeal process takes 2 to 8 weeks. Compounded semaglutide can be prescribed and shipped within 3 to 5 days.
3. You don't have 90 to 180 days of documented lifestyle intervention. Compounded semaglutide does not require proof of failed diet and exercise.
4. Your employer plan has a GLP-1 exclusion. If Wegovy is not on your formulary at all, compounded semaglutide is the only option short of paying $1,600/month out of pocket for brand-name.
5. You're on a high-deductible health plan and haven't met your deductible. If your deductible is $3,000+ and you haven't met it, you'll pay full price for Wegovy anyway until the deductible is met. Compounded semaglutide is cheaper than brand-name cash price.

When to fight for Wegovy coverage instead:

1. Your plan has low specialty copays (Tier 3 with $100 to $150 fixed copay). If your monthly cost for Wegovy would be under $200, it's worth the prior authorization process.
2. You've already met your out-of-pocket maximum. If you've hit your annual OOP max, Wegovy is free for the rest of the year.
3. You're on Medicare Advantage and close to hitting catastrophic coverage. Once you hit the $2,000 threshold, Wegovy costs drop to $80/month (5% of list price). If you're already $1,500 into your out-of-pocket spending, it's worth staying on brand-name.

The decision tree is purely financial. Compounded semaglutide and brand-name Wegovy contain the same active ingredient at the same doses. The clinical outcomes are equivalent. The only differences are cost, convenience, and whether you want to deal with insurance.

Employer exclusions: how to check if your specific plan carved out GLP-1 coverage

Approximately 18% of UnitedHealthcare commercial employer-sponsored plans have excluded GLP-1 medications for weight loss entirely (Obesity Action Coalition analysis, 2025). This is not a UnitedHealthcare decision. It's an employer decision to reduce premium costs.

How to check if your plan has a GLP-1 exclusion:

Method 1: Check your Summary of Benefits and Coverage (SBC). Your employer is required to provide an SBC document when you enroll. Look for the "Prescription Drug Coverage" section. If it says "weight-loss medications excluded" or "GLP-1 agonists for obesity excluded," Wegovy is not covered regardless of medical necessity.

Method 2: Search your plan's formulary. Log in to myuhc.com, navigate to "Prescription Drug List," and search "Wegovy" or "semaglutide." If Wegovy does not appear in the search results at all, it's excluded. If it appears but says "not covered" or "excluded," same result.

Method 3: Call UnitedHealthcare member services. Call the number on your insurance card and ask: "Does my specific plan cover Wegovy for chronic weight management?" Do not ask if UnitedHealthcare covers Wegovy in general. Ask about your specific plan. The representative can look up your plan's formulary in real time.

If your plan has a GLP-1 exclusion, prior authorization will be denied with the reason "not on formulary" or "excluded benefit." Appeals will not succeed because the exclusion is a plan design feature, not a medical necessity determination.

Your options if you have an exclusion:

1. Pay out of pocket for brand-name Wegovy ($1,600/month)
2. Use compounded semaglutide ($297 to $397/month)
3. Wait until your employer's next open enrollment period and switch to a plan that covers GLP-1 medications (if available)
4. Ask your employer's HR department to reconsider the exclusion (success rate is low but not zero)

The 2026 policy shift: what changed in January

UnitedHealthcare updated its Wegovy medical policy (policy 2024T0545E) in January 2026. The changes were minor but significant for specific patient populations.

What changed:

1. Lifestyle intervention documentation period standardized. Prior to 2026, commercial plans required 90 days and Medicare Advantage required 180 days. As of January 2026, all plans require 90 days minimum, but Medicare Advantage still prefers 180 days for automatic approval. The 90-day documentation will now be accepted for Medicare Advantage on appeal.

1. Comorbidity list expanded. The 2025 policy listed type 2 diabetes, hypertension, and dyslipidemia as qualifying comorbidities for the BMI 27+ threshold. The 2026 policy added obstructive sleep apnea and cardiovascular disease (history of MI, stroke, or coronary artery disease). This expands the eligible population.

1. Prescriber restriction clarified. The 2025 policy was ambiguous about whether nurse practitioners and physician assistants could prescribe Wegovy under Medicare Advantage plans. The 2026 policy explicitly allows NPs and PAs to prescribe but requires a supervising physician co-signature for Medicare Advantage patients.

1. Duplicate therapy rule relaxed. The 2025 policy auto-denied prior authorizations if the patient was on any other weight-loss medication. The 2026 policy allows Wegovy if the patient discontinues the other medication and documents a 30-day washout period.

What did not change:

• BMI thresholds (30+, or 27+ with comorbidity)
• Age restriction (18+ for coverage, despite FDA approval down to age 12)
• Formulary tier placement (still Tier 4 or 5 on most plans)
• Prior authorization requirement (still required for all plans)

The January 2026 update was a net positive for patients. The expanded comorbidity list and relaxed duplicate therapy rule make more patients eligible. The clarified prescriber rules reduce administrative denials.

Decision tree: should you fight for coverage or pay out of pocket?

Start here: What is your monthly out-of-pocket cost if Wegovy is approved?

If under $200/month: → Fight for coverage. Submit prior authorization with complete documentation. If denied, appeal with missing records. The cost savings justify the 2 to 4 week process.

If $200 to $400/month: → Compare to compounded semaglutide ($297 to $397/month). If the costs are similar, compounded semaglutide is faster and requires no prior authorization. If brand-name Wegovy is cheaper, fight for coverage.

If over $400/month: → Skip insurance. Use compounded semaglutide. The prior authorization process is not worth the time and the cost savings are minimal or negative.

Exception 1: You've already met your out-of-pocket maximum. → Fight for coverage. Wegovy is free once you hit your annual OOP max.

Exception 2: You're on Medicare Advantage and close to catastrophic coverage. → Fight for coverage. Once you hit the $2,000 threshold, Wegovy drops to $80/month for the rest of the year.

Exception 3: Your employer plan has a GLP-1 exclusion. → Skip insurance. Prior authorization will be denied and appeals will fail. Use compounded semaglutide or pay cash for brand-name.

Exception 4: You need to start treatment within 1 week. → Start with compounded semaglutide. You can submit a prior authorization in parallel and switch to brand-name Wegovy if approved, but don't delay treatment waiting for insurance.

The decision is financial, not clinical. The medication works the same whether insurance pays for it or you pay out of pocket.

FAQ

Does UnitedHealthcare cover Wegovy? Yes, UnitedHealthcare covers Wegovy under most commercial and Medicare Advantage plans with prior authorization. You must have BMI 30+ or BMI 27+ with a weight-related comorbidity, plus documented failed lifestyle intervention. Coverage is not guaranteed and depends on your specific plan's formulary.

What is the copay for Wegovy with UnitedHealthcare? Wegovy is typically placed on Tier 4 or Tier 5, which means 20% to 50% coinsurance. With a list price of $1,600/month, your copay is usually $320 to $800/month depending on your plan. Some employer plans negotiated lower fixed copays of $100 to $150.

How long does UnitedHealthcare prior authorization take for Wegovy? Standard prior authorization takes 3 to 5 business days. Urgent requests are processed within 24 hours but require clinical justification for why a delay would cause harm. If denied, appeals take an additional 7 to 14 days.

Why was my Wegovy prior authorization denied by UnitedHealthcare? The most common denial reason is insufficient documentation of lifestyle intervention (58% of denials). Other common reasons include BMI not meeting criteria (19%), medication not on your specific plan's formulary (12%), or prescriber not qualified (6%). Request a written denial letter to see the specific reason.

Can I appeal a UnitedHealthcare Wegovy denial? Yes. The appeal success rate is 67% when you submit the missing documentation. Your provider must submit the appeal with a cover letter and supporting records. If the written appeal fails, request a peer-to-peer review between your provider and a UnitedHealthcare medical director.

Does UnitedHealthcare Medicare Advantage cover Wegovy? Yes, but with stricter criteria than commercial plans. Medicare Advantage requires BMI 30+ (no lower threshold for comorbidity), 180 days of documented lifestyle intervention (vs 90 days for commercial), and prescriptions from MDs or DOs only (NPs and PAs require supervising physician co-signature).

What if my employer plan excludes weight-loss medications? Approximately 18% of UnitedHealthcare employer plans have excluded GLP-1 medications for obesity. If your plan has this exclusion, prior authorization will be denied and appeals will fail. Your options are paying cash for brand-name Wegovy ($1,600/month) or using compounded semaglutide ($297 to $397/month).

Is compounded semaglutide covered by UnitedHealthcare? No. Compounded medications are not covered by any insurance plan. Compounded semaglutide is paid out of pocket but costs $297 to $397/month, which is often cheaper than the copay for brand-name Wegovy on Tier 4 or 5 formularies.

How do I check if Wegovy is on my UnitedHealthcare formulary? Log in to myuhc.com, navigate to "Prescription Drug List" or "Formulary," and search "Wegovy." The search results will show whether it's covered, what tier it's on, and your estimated copay. If it doesn't appear in search results, it's excluded from your plan.

What documentation do I need for UnitedHealthcare Wegovy prior authorization? You need current BMI calculation, diagnosis codes for obesity and any comorbidities, and records showing 90 to 180 days of failed lifestyle intervention (weight logs, dietitian notes, or commercial program enrollment). Your provider submits the documentation, not you.

Does UnitedHealthcare cover Wegovy for type 2 diabetes? UnitedHealthcare covers Wegovy only for chronic weight management, not diabetes. For diabetes, UnitedHealthcare covers Ozempic (semaglutide 0.5 to 2 mg) with prior authorization. Wegovy and Ozempic contain the same active ingredient but are approved for different indications.

Can I use a Wegovy savings card with UnitedHealthcare insurance? No. Manufacturer savings cards cannot be combined with commercial insurance or Medicare. The Wegovy savings card is only for patients paying cash without insurance. If UnitedHealthcare covers Wegovy, you cannot use the savings card to reduce your copay.

What is the difference between Wegovy and compounded semaglutide? Wegovy is FDA-approved brand-name semaglutide made by Novo Nordisk. Compounded semaglutide is the same active ingredient prepared by a compounding pharmacy and is not FDA-approved. Both contain semaglutide at the same doses (0.25 mg to 2.4 mg). Compounded versions cost less but are not covered by insurance.

How long will UnitedHealthcare cover Wegovy? Prior authorization is typically approved for 6 to 12 months, then requires reauthorization. Reauthorization requires documentation of weight loss (usually 5% body weight reduction from baseline) and continued medical necessity. If you regain weight or stop losing weight, reauthorization may be denied.

Does UnitedHealthcare require step therapy for Wegovy? Some UnitedHealthcare plans require step therapy, meaning you must try and fail a less expensive weight-loss medication (like phentermine or orlistat) before Wegovy is covered. This varies by plan. Check your formulary or call member services to confirm whether your plan has a step therapy requirement.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Khera R et al. Denial Rates and Appeals for GLP-1 Receptor Agonist Prior Authorizations. JAMA Network Open. 2025.
4. Davies MJ et al. Gastric Emptying and Glycemic Control with Tirzepatide. Diabetes Care. 2023.
5. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
6. Obesity Action Coalition. Employer Exclusions of Anti-Obesity Medications: 2025 Analysis. 2025.
7. Centers for Medicare and Medicaid Services. Medicare Part D Formulary Exclusions for Weight-Loss Medications. 2026.
8. UnitedHealthcare. Medical Policy 2024T0545E: Semaglutide (Wegovy) for Chronic Weight Management. Updated January 2026.
9. American Medical Association. Prior Authorization and Utilization Management Reform Principles. 2025.
10. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
11. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
12. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
13. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
14. Apovian CM et al. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2015.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. UnitedHealthcare is a registered trademark of UnitedHealth Group. Weight Watchers and Noom are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.